SCHEMBL23601015

SCHEMBL23601015

CN(c1cccc(-c2nnc(C3CC3)s2)c1)c1nc2nncn2c2cc(Cl)ccc12

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.37
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
MAT2A P31153 1/20 0.33
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
HSD17B10 Q99714 2/20 0.32
TP53 P04637 2/20 0.32
MAPT P10636 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
GFER P55789 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HRH3 Q9Y5N1 1/20 0.31
HRH4 Q9H3N8 1/20 0.30
HPGD P15428 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31169430 1.00 EGFR (0.37) EGFRFNTAFNTBMAT2AKDM4E
SCHEMBL23578328 0.84 MAT2A (0.35) FNTAFNTBMAT2AKDM4EALDH1A1
SCHEMBL23577357 0.83 FNTA (0.35) FNTAFNTBMAT2AKDM4EALDH1A1
SCHEMBL23601235 0.82 FNTA (0.40) FNTAFNTBMAT2AKDM4EALDH1A1
SCHEMBL30920925 0.82 TP53 (0.39) FNTAFNTBMAT2ATP53MAPT
SCHEMBL29909768 0.82 FNTA (0.40) FNTAFNTBMAT2AKDM4EALDH1A1
SCHEMBL23577377 0.81 FNTA (0.34) FNTAFNTBMAT2ATP53MAPT
SCHEMBL23600473 0.81 FNTA (0.36) FNTAFNTBMAT2AKDM4EALDH1A1
SCHEMBL23601440 0.81 FNTA (0.34) FNTAFNTBMAT2AKDM4EALDH1A1
SCHEMBL23601014 0.81 MAPT (0.41) FNTAFNTBKDM4EALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK EGFR 1239/4885FNTA 968/4885FNTB 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.